Pharmacist and CEO Jocelyn Freimuth Weighs Hormone Therapy's Second Act

On February 12, 2026, the FDA approved labeling changes that remove boxed warnings about cardiovascular disease, breast cancer, and probable dementia from six menopausal hormone therapy products. Four treatment categories are covered: systemic combination therapy, systemic estrogen alone, systemic progestogen alone, and topical vaginal estrogen.

Regulators stripped menopause hormone therapy of its strongest warnings in early 2026, reopening a treatment conversation that a generation of patients largely never had.

One pair of numbers shows what those warnings did. Roughly 41 million American women were between 45 and 64 in 2020, and about 2 million women in the 46-to-65 bracket received hormone therapy prescriptions that year. Two decades of black-box labeling sat between demand and treatment.

Jocelyn Freimuth works where label changes meet actual patients. An adjunct professor of pharmacy whose 15-plus years in healthcare run from nursing through compounding practice to executive leadership, she co-founded and leads the healthcare consulting firm Camino Compass and has built made-to-order hormone preparations for patients whom mass-produced options never quite fit. A label rewrite of this size, in Jocelyn Freimuth's reading, moves the hard questions from the pharmacy shelf to the exam room.

Why Did Hormone Therapy Need a Second Look?

Boxed warnings date to the Women's Health Initiative era of the early 2000s, when trial results linking hormone therapy to cardiovascular and cancer risks collapsed prescribing almost overnight. Clinicians stopped offering the treatment, patients stopped asking for it, and menopause management largely fell out of medical training along the way. Symptoms did not get the memo: hot flashes, sleep disruption, bone loss, and genitourinary changes kept arriving for millions of women each year.

Vasomotor symptoms often persist for years, and untreated bone loss compounds silently across the same stretch. Deterrence in medicine is never free; it simply bills a different account. This bill landed on a generation of women who cycled through sleep aids, antidepressants, and reassurance while the treatment designed for their condition sat behind a warning built from other patients' risk profiles.

Later analyses complicated the original alarm. Study populations skewed years past menopause onset, and age turned out to matter enormously. FDA's announcement cites randomized evidence that women who start therapy within ten years of menopause onset, typically before age 60, show reductions in all-cause mortality and fractures.

Timing turned out to carry the risk story. Younger patients near menopause onset face a different calculus than older patients a decade past it, a distinction the original warnings never drew. FDA Commissioner Marty Makary framed the change around exactly that group: "Women face symptoms of menopause that can last for years, and our efforts will help these women make well-informed medical decisions." Timing, not the therapy alone, is the variable the new labels finally acknowledge.

What the New Labels Change, and What They Don't

Clinical societies drew the same line the evidence does. The Menopause Society backed the removal for low-dose vaginal estrogen, calling it a safe and effective therapy for a condition affecting most menopausal women and noting the old boxed warning may itself have deterred use. Systemic estrogen drew more caution: it "still comes with potential risks in certain individuals that should be reviewed in detail."

Risk language does not vanish from these products, either. Detailed safety information moves out of the boxed format and stays in the prescribing information, where clinicians are expected to weigh it case by case rather than read it as a blanket stop sign. What changed is the default, from presumed danger to presumed discussion. Six products carry the new labels today; how far the rest of the category follows rides on the same evidence review.

Individual assessment, the ground Jocelyn Freimuth has worked across her whole career, is the part no label can perform. Comorbidities, personal and family history, symptom severity, and patient preference all move the recommendation, and they move it differently for a 51-year-old than for a 68-year-old. Removing a warning widens the conversation without settling it.

Jocelyn Freimuth's Case for the Guided Decision

Pharmacists inherit a specific job in that widened conversation. Menopausal regimens come in dozens of doses, routes, and combinations, from pills and patches to gels, rings, and creams, and each route carries its own absorption profile and practical tradeoffs. Matching one to a patient takes medication-level fluency that a fifteen-minute physician visit rarely has room for.

Jocelyn Freimuth's summary of the moment is blunt: "A label change opens the door. It does not walk a patient through it."

Follow-through matters as much as the first choice. Hormone regimens get adjusted over months as symptoms respond and side effects surface, which makes the refill counter a recurring checkpoint nothing else in the care system replicates. One who knows what week six should feel like stays the course; one left guessing tends to quit.

Compounded hormone preparations add a second layer to the counseling job. Demand historically spilled toward made-to-order formulations when approved products did not fit a patient's needs, and those preparations carry no FDA-reviewed labeling at all. Oversight differs too, running through state pharmacy boards rather than federal drug review, which raises the stakes on the professional preparing and explaining the therapy. Approved or compounded, warned or unwarned, the constant in Jocelyn Freimuth's framing is a professional walking each patient through what the label cannot say about her specific body and history.

Where Does Menopause Care Go From Here?

Prescribing will almost certainly rise, and the bottleneck will shift to expertise. A generation of clinicians trained under the boxed warnings, and many learned to avoid the topic rather than master it. Medical and pharmacy curricula, continuing education, and patient-facing guidance all have twenty years of catching up to do.

Patients will arrive faster than the training does. Employer benefits programs, search trends, and a wave of midlife-health media have already moved menopause from private complaint to public agenda, and appointment demand follows attention. Clinical societies have begun credentialing practitioners in menopause care, scaffolding that barely existed while the warnings stood.

Education is the ground Jocelyn Freimuth already works: teaching future pharmacists, speaking to professional audiences in the United States and internationally, and advising the practices and virtual-care companies where much of the new demand will land. Forty-one million women sat on one side of the old warning labels while two million got treated. Whatever fills that gap will be built out of informed conversations, and the professionals ready to hold them are about to be busy.